Listed on the Nasdaq as ticker symbol GNCA, Genocea Biosciences works with T cells to develop the next generation of vaccines.
In the initial public offering (IPO) Citigroup and Cowen and Company acted as joint book-running managers. The company priced 5.5 million shares at $12 per share for an initial market cap of around $207m.
This adds to the $88 million in funding already raised from Polaris Venture Partners (16.3% pre-IPO stake), Lux Ventures (14.8%), S.R. One – the global venture arm of GlaxoSmithKline (13%), Johnson & Johnson Development Corporation (11.7%), CVF (9.3%), Skyline Ventures (8.8%), Cycad Group (6.6%), Auriga Ventures (6.5%), The Bill & Melinda Gates Foundation (6.2%) and Morningside Ventures.